Review of Raynaud’s phenomenon: pathomechanisms, diagnosis and treatment
DOI:
https://doi.org/10.12775/JEHS.2024.72.51508Keywords
Raynaud’s phenomenon, Raynauld’s disease, Raynauld’s syndrome, diagnosis, treatmentAbstract
Introduction: Raynaud’s phenomenon (RP) is a quite common but often unrecognised vasospastic condition of the peripheral vessels. This may happen after exposure to the cold, stress, vibrations or a wide range of medical conditions. It causes episodic colour changes of the digits, firstly there is a pallor, followed by cyanosis and/or redness, usually with pain. Raynaud’s phenomenon can be primary (i.e. Raynaud’s disease) or secondary (i.e. Raynaud’s syndrome) to underlying disease.
Aim of the study: The aim of the study was to discuss the complex and incompletely understood pathophysiology of Raynaud’s phenomenon and to evaluate treatment approaches of both ‘uncomplicated’ - mostly primary and ‘complicated’ - mostly secondary Raynaud’s phenomenon.
State of knowledge: Raynaud’s phenomenon is a common disorder with an unclear pathophysiology. Although many treatment approaches have been reported, there is still no cure or gold standard therapy. Further investigations into treatment are required.
Conclusions: Future research is needed to understand the complex pathogenesis of RP and to develop optimised approaches to management.
References
Choi E, Henkin S. Raynaud’s phenomenon and related vasospastic disorders. Vascular Medicine. 2021;(1):56-70. doi:10.1177/1358863x20983455
Temprano K. A Review of Raynaud’s Disease - PMC. PubMed Central (PMC). 2016;(113(2)):123-126. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139949/ (Accessed May 14, 2024)
Herrick AL. Raynaud’s phenomenon. Journal of Scleroderma and Related Disorders. 2019;(2):89-101. doi:10.1177/2397198319826467
Gualtierotti R, Ingegnoli F, Griffini S, et al. Detection of early endothelial damage in patients with Raynaud’s phenomenon. Microvascular Research. Published online September 2017:22-28. doi:10.1016/j.mvr.2017.04.004 (Accessed May 14, 2024)
Herrick A, Muir L. Raynaud’s phenomenon (secondary) - PMC. PubMed Central (PMC). Published online October 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200538/ (Accessed May 14, 2024)
Pope JE. Raynaud’s phenomenon (primary) - PMC. PubMed Central (PMC). Published October 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794700/ (Accessed May 14, 2024)
Haque A, Hughes M. Raynaud’s phenomenon. Clinical Medicine. 2020;(6):580-587. doi:10.7861/clinmed.2020-0754
Zamora MR, O’Brien RF, Rutherford RB. Serum endothelin-1 concentrations and cold provocation in primary Raynaud’s phenomenon. The Lancet. 1990;(8724):1144-1147. doi:10.1016/0140-6736(90)92766-b
Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud’s Phenomenon: A Brief Review of the Underlying Mechanisms. Frontiers in Pharmacology. Published online November 16, 2016. doi:10.3389/fphar.2016.00438 (Accessed May 14, 2024)
Smyth AE. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud’s phenomenon. Annals of the Rheumatic Diseases. 2000;(11):870-874. doi:10.1136/ard.59.11.870
Żuk J, Snarska-Drygalska A, Malinowski K, Papuga-Szela E, Natorska J, Undas A. Unfavourably altered plasma clot properties in patients with primary Raynaud’s phenomenon: association with venous thromboembolism | Journal of Thrombosis and Thrombolysis. SpringerLink. Published online 2019:248-254. http://link.springer.com/article/10.1007/s11239-019-01805-0 (Accessed May 14, 2024)
Abdulle AE, Diercks GFH, Feelisch M, Mulder DJ, Goor H van. The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy. Frontiers in Physiology. Published online August 24, 2018. doi:10.3389/fphys.2018.01177 (Accessed May 14, 2024)
Munir S, Freidin MB, Brain S, Williams FMK. Association of Raynaud’s phenomenon with a polymorphism in the NOS1 gene. Crispin JC, ed. PLOS ONE. 2018;(4):e0196279. doi:10.1371/journal.pone.0196279
Smith V, Herrick AL, Ingegnoli F, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud’s phenomenon and systemic sclerosis. Autoimmunity Reviews. 2020;(3):102458. doi:10.1016/j.autrev.2020.102458
Musa R, Qurie A. Raynaud Disease - StatPearls - NCBI Bookshelf. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK499833// (Accessed May 14, 2024)
Haque A, Hughes M. Raynaud’s phenomenon. Clinical Medicine. 2020;(6):580-587. doi:10.7861/clinmed.2020-0754
Maricq HR, Carwile LeRoy E. Patterns of finger capillary abnormalities in connective tissue disease by “wide‐field” microscopy. Arthritis & Rheumatism. 1973;(5):619-628. doi:10.1002/art.1780160506
Haque A, Hughes M. Raynaud’s phenomenon. Clinical Medicine. 2020;(6):580-587. doi:10.7861/clinmed.2020-0754
Wigley FM, Flavahan NA. Raynaud’s Phenomenon. Campion EW, ed. New England Journal of Medicine. 2016;(6):556-565. doi:10.1056/nejmra1507638
Maltez N, Maxwell LJ, Rirash F, et al. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud’s phenomenon. Cochrane Database of Systematic Reviews. 2023;(11). doi:10.1002/14651858.cd014089
Hotkar MS, Avachat AM, Bhosale SS, Oswal YM. Preliminary investigation of topical nitroglycerin formulations containing natural wound healing agent in diabetes‐induced foot ulcer. International Wound Journal. 2013;(2):210-217. doi:10.1111/iwj.12084
Qiu O, Chan T, Luen M, Cruz JE, Hermes-DeSantis ER. Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review. Rheumatology International. 2018;(12):2209-2216. doi:10.1007/s00296-018-4119-9
Pintea Bentea G, Wauters A, Wautrecht J-C, Cogan E. Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients. Vascular Medicine. 2020;(6):559-568. doi:10.1177/1358863x2095390
Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis & Rheumatism. 1999;(12):2646-2655. doi:10.1002/1529-0131(199912)42:12<2646::aid-anr21>3.0.co;2-t
Górska K, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Stawczyk-Macieja M, Wierzba K, Nowicki RJ. Raynaud’s phenomenon as an interdisciplinary problem. Dermatology Review. Published online 2017:499-508. doi:10.5114/dr.2017.71215
Harding SE, Tingey PC, Pope J, et al. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews. Published online April 27, 1998. doi:10.1002/14651858.cd000956 (Accessed May 14, 2024)
Wollersheim H, Thien T, Fennis J, Van Eiteren P, Laar AV. Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clinical Pharmacology and Therapeutics. 1986;(2):219-225. doi:10.1038/clpt.1986.166
Bello RJ, Cooney CM, Melamed E, et al. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma‐Associated Raynaud’s Phenomenon: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. Arthritis & Rheumatology. 2017;(8):1661-1669. doi:10.1002/art.40123
Pace CS, Merritt WH. Extended Periarterial Sympathectomy: Evaluation of Long-term Outcomes. HAND. 2017;(4):395-402. doi:10.1177/1558944717715119
Digital Periarterial Sympathectomy for Severe Ischemia of Raynaud’s Syndrome. Vascular Disease Management. Published January 2007. https://www.hmpgloballearningnetwork.com/site/vdm/content/digital-periarterial-sympathectomy-severe-ischemia-raynaudaos-syndrome (Accessed May 14, 2024)
Cina C, Cina M, Clase C. Endoscopic thoracic sympathectomy for hyperhidrosis: Technique and results. Journal of Minimal Access Surgery. 2007;(4):132. doi:10.4103/0972-9941.38907
Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. Journal of Thoracic Disease. 2017;(S3):S178-S192. doi:10.21037/jtd.2017.04.04
van Roon AM, Kuijpers M, van de Zande SC, et al. Treatment of resistant Raynaud’s phenomenon with single-port thoracoscopic sympathectomy: a novel minimally invasive endoscopic technique. Rheumatology. 2019;(5):1021-1025. doi:10.1093/rheumatology/kez386
Thune TH, Ladegaard L, Licht PB. Thoracoscopic Sympathectomy for Raynaud’s Phenomenon—A Long Term Follow-up Study. European Journal of Vascular and Endovascular Surgery. 2006;(2):198-202. doi:10.1016/j.ejvs.2006.01.017
Cameron A. Letter to the Editor re: Thorascopic Sympathectomy or Raynaud’s Phenomenon – A Long Term Follow-up Study. Thune TH, Ladegard L & Licht PB. Eur J Vasc Endovasc Surg 32, 198–202 (2006). European Journal of Vascular and Endovascular Surgery. 2007;(1):133. doi:10.1016/j.ejvs.2006.09.020
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Marczyk, Karolina Makowska, Marta Billewicz, Laura Lis, Aleksandra Turek, Adam Popiołek, Julia Pietrzykowska, Oksana Zatorska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 303
Number of citations: 0